Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Drug Discov Today ; 22(3): 526-533, 2017 03.
Article in English | MEDLINE | ID: mdl-27666194

ABSTRACT

The flavoenzyme DprE1 catalyses a crucial step in arabinan production for cell wall biosynthesis in Mycobacterium tuberculosis and is a highly vulnerable drug target. It was first discovered using benzothiazinones (BTZ): exquisitely potent bactericidal agents that are being developed as drugs to treat tuberculosis. Subsequently, many compounds with diverse scaffolds were found to act as either covalent or noncovalent DprE1 inhibitors. Covalent inhibitors, like the BTZ, are all nitroaromatic compounds that serve as suicide substrates after DprE1-mediated nitroreduction. Here, we describe how high-resolution structures of DprE1, alone and in complex with various ligands, explain enzyme activity and inhibition.


Subject(s)
Alcohol Oxidoreductases/antagonists & inhibitors , Alcohol Oxidoreductases/chemistry , Antitubercular Agents/pharmacology , Bacterial Proteins/antagonists & inhibitors , Bacterial Proteins/chemistry , Alcohol Oxidoreductases/metabolism , Animals , Antitubercular Agents/therapeutic use , Bacterial Proteins/metabolism , Humans , Mycobacterium tuberculosis/drug effects , Mycobacterium tuberculosis/metabolism , Protein Conformation , Tuberculosis/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...